Future Outlook of Global Sjogrens Syndrome Market to be defined by Various Off-Label Treatments

Published Date : Apr 11, 2016

ALBANY, New York, April 11, 2016: MarketResearchReports.biz has added a new research report to its repository. The report, titled “Opportunity Analyzer: Sjogrens Syndrome - Opportunity Analysis and Forecast To 2024,” offers a comprehensive overview of the global Sjogrens syndrome market and points out the key factors affecting the growth of the market. The report analyzes the primary unmet needs in this market and how the drugs under development will fulfill those needs. The current treatment options have been discussed in the report, along with the assessment and valuation of the pipeline drugs. The report further analyzes the growth opportunities for the market across some of the key regions.

Sjgrens syndrome refers to a chronic, slow progressing autoimmune disease that mostly affects middle-aged women. The report discusses the various clinical symptoms of the disease such as the lymphocytic infiltration of the exocrine glands, mainly the salivary and lacrimal glands that leads to reduced secretions, along with oral and ocular dryness. The disease causes many systemic manifestations, targeting various parts of the body.

Offering an overview of the global Sjgrens syndrome market, the report discusses the disease background, along with various risk factors and general preventive measures. The diagnosed cases of primary Sjgrens syndrome have been categorized on the basis of age and sex. Describing the current treatment options, the report lists down the major pharmaceutical brands and their products. Salagen (Pilocarpine Hydrochloride) and Evoxac (Cevimeline Hydrochloride) are the major cholinergic agonists used for the treatment of the disease. Salagen is primarily prescribed to treat dry mouth in Sjogrens syndrome. Evoxac is also saliva production stimulator.

The report further discusses the various off-label treatments and drug classes including tear and saliva substitutes, topical ophthalmic corticosteroids such as Fluorometholone, Prednisolone, and Loteprednol, cyclosporine ophthalmic emulsion such as Ikervis, Restasis, and Papilock Mini, antimalarial agents such as Hydroxycholoroquine, systemic corticosteroids such as Methylprednisolone and Prednisolone, biologic agents such as Rituxan (Rituximab), and other systemic immunosuppressive therapies.

The report analyzes the unmet needs and opportunities in the global Sjgrens syndrome market with focus on early disease diagnosis, treatment guidelines to improve patient access to therapies, treatments with improved efficacy, and improved public and patient awareness regarding the disease. Taking a note of the research and development activities in the market, the report discusses the evaluation of biologic therapies marketed for other autoimmune diseases and the inhibition of immunological mechanisms involved in Sjgrens syndrome. The report further provides information about the clinical trial designs in terms of patient number and efficacy endpoints.

Assessment of pipeline drugs for the treatment of Sjgrens syndrome has been included in the report, along with innovative early-stage approaches. Orencia (Abatacept) is among the promising drugs in clinical development. The report projects the growth of the Sjgrens syndrome market across the U.S., Japan, and the European Union by 2024.